Delving into the Latest Updates on Virchow Biotech Pvt Ltd. with Synapse

Overview

An open label, balanced, randomized, two-treatment, two-sequence, two-period, single-dose,cross-over, bioequivalence study of Liraglutide 0.6 mg Injection (6 mg/mL) (Test) of VirchowBiotech Private Limited, India and VictozaÂ® (Liraglutide) injection in pre-filled pen 0.6 mg (6 mg/mL) of Novo Nordisk A/S Novo AllÃ© DK-2880 BagsvÃ¦rd, Denmark in normal, healthy adult,human subjects under fasting conditions. - Nil

Start Date26 Dec 2022

Sponsor / Collaborator

Virchow Biotech Pvt Ltd.

CTRI/2022/10/046212 / Active, not recruitingPhase 3

Comparative pharmacokinetic, pharmacodynamic,safety, efficacy and immunogenecity study ofVBRTXM01 (Virchow Rituximab) versus Ristova(Roche Rituximab) in patients with RheumatoidArthritis - Nil

Start Date22 Oct 2022

Sponsor / Collaborator

Virchow Biotech Pvt Ltd.

100 Clinical Results associated with Virchow Biotech Pvt Ltd.

Login to view more data

0 Patents (Medical) associated with Virchow Biotech Pvt Ltd.

Login to view more data

11

Literatures (Medical) associated with Virchow Biotech Pvt Ltd.

21 Sep 2024·Molecular Simulation

Screening of DNMT3A inhibitors from phytochemicals using molecular docking and molecular dynamics simulation for their anti-cancer potential

Author: Prabhu, Dhamodharan ; Pawar, Smita C. ; Singh, Anjuvan ; Perugu, Shyam ; Kour, Satbir ; Vuree, Sugunakar ; Biswas, Indrani

20 May 2021·The Journal of Infectious Diseases

A Phase II Safety and Efficacy Study on Prognosis of Moderate Pneumonia in Coronavirus Disease 2019 Patients With Regular Intravenous Immunoglobulin Therapy

Article

Author: Raman, R S ; Rakesh Kartha, R ; Bafna, Varun ; Bhagwan Barge, Vijaykumar ; Dandu, Himanshu ; Raghuram, Thummala C ; Aravinda, Vishaly T ; Anil Kumar, Darivenula

AbstractBackgroundCurrently, there is no specific drug for the treatment of coronavirus disease 2019 (COVID-19). Therapeutic benefits of intravenous immunoglobulin (IVIG) have been demonstrated in wide range of diseases. The present study is conducted to evaluate the safety and efficacy of IVIG in the treatment of COVID-19 patients with moderate pneumonia.MethodsAn open-label, multicenter, comparative, randomized study was conducted on COVID-19 patients with moderate pneumonia. One hundred eligible patients were randomized in 1:1 ratio either to receive IVIG + standard of care (SOC) or SOC.ResultsDuration of hospital stay was significantly shorter in the IVIG group compared with that of SOC alone (7.7 vs 17.5 days). Duration for normalization of body temperature, oxygen saturation, and mechanical ventilation were significantly shorter in IVIG compared with SOC. Percentages of patients on mechanical ventilation in 2 groups were not significantly different (24% vs 38%). Median time to reverse-transcription polymerase chain reaction negativity was significantly shorter with IVIG than SOC (7 vs 18 days). There were only mild to moderate adverse events in both groups except for 1 patient (2%), who died in SOC.ConclusionsIntravenous immunoglobulin was safe and efficacious as an adjuvant with other antiviral drugs in the treatment of COVID-19.

01 Feb 2018·Journal of Pharmaceutical SciencesQ3 · MEDICINE

Potential of Cationic-Polymeric Nanoparticles for Oral Delivery of Naringenin: In Vitro and In Vivo Investigations

Q3 · MEDICINE

Article

Author: Patel, Ravi R ; Chaurasia, Sundeep ; Vure, Prasad ; Mishra, Brahmeshwar

The objective of the study was to improve the bioavailability and anticancer potential of naringenin (NRG) by developing a drug-loaded polymeric nanodelivery system. NRG-loaded eudragit E100 nanoparticle (NRG-EE100-NPs) system was developed and physicochemically characterized. In vivo pharmacokinetic and in vitro cytotoxicity abilities of the NRG-EE100-NPs were investigated. In vivo anticancer activity was evaluated in murine BALB/c mice-bearing colorectal tumor. The NRG-EE100-NPs had an optimum mean particle size (430.42 ± 5.78 nm), polydispersity index (0.283 ± 0.089) with percent entrapment efficiency (68.83 ± 3.45%). The NRG-EE100-NPs demonstrated significant higher bioavailability (∼96-fold; p <0.05) as well as cytotoxicity (∼16-fold; p <0.001) as compared to free NRG. Furthermore, NRG-EE100-NPs indicated significant tumor suppression (p <0.01) subsequently improvement in survival rate compared to free NRG in vivo. Thus, the physicochemical properties and colorectal cancer efficacy of NRG were improved by successful encapsulating in cationic-polymeric nanoparticle system.

100 Deals associated with Virchow Biotech Pvt Ltd.

Login to view more data

100 Translational Medicine associated with Virchow Biotech Pvt Ltd.

Login to view more data